Differential Gene Expression in Benign Prostate Epithelium of Men with and without Prostate Cancer: Evidence for a Prostate Cancer Field Effect

Background: Several malignancies are known to exhibit a “field effect,” whereby regions beyond tumor boundaries harbor histologic or molecular changes that are associated with cancer. We sought to determine if histologically benign prostate epithelium collected from men with prostate cancer exhibits features indicative of premalignancy or field effect. Experimental Design: Prostate needle biopsies from 15 men with high-grade (Gleason 8-10) prostate cancer and 15 age- and body mass index–matched controls were identified from a biospecimen repository. Benign epithelia from each patient were isolated by laser capture microdissection. RNA was isolated, amplified, and used for microarray hybridization. Quantitative PCR was used to determine the expression of specific genes of interest. Alterations in protein expression were analyzed through immunohistochemistry. Results: Overall patterns of gene expression in microdissected benign prostate-associated benign epithelium (BABE) and cancer-associated benign epithelium (CABE) were similar. Two genes previously associated with prostate cancer, PSMA and SSTR1, were significantly upregulated in the CABE group (false discovery rate <1%). Expression of other prostate cancer–associated genes, including ERG, HOXC4, HOXC5, and MME, were also increased in CABE by quantitative reverse transcription-PCR, although other genes commonly altered in prostate cancer were not different between the BABE and CABE samples. The expression of MME and PSMA proteins on immunohistochemistry coincided with their mRNA alterations. Conclusion: Gene expression profiles between benign epithelia of patients with and without prostate cancer are very similar. However, these tissues exhibit differences in the expression levels of several genes previously associated with prostate cancer development or progression. These differences may comprise a field effect and represent early events in carcinogenesis. Clin Cancer Res; 16(22); 5414–23. ©2010 AACR.

[1]  T. Barrette,et al.  Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. , 2002, Cancer research.

[2]  D. Bacich,et al.  Prostate specific membrane antigen (PSMA) expression gives prostate cancer cells a growth advantage in a physiologically relevant folate environment in vitro , 2006, The Prostate.

[3]  R. Haba,et al.  Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. , 2005, The Journal of urology.

[4]  George L. Wright,et al.  Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.

[5]  Lang Li,et al.  Heterogeneity of Gleason grade in multifocal adenocarcinoma of the prostate , 2004, Cancer.

[6]  B. Suffoletto,et al.  Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[7]  Elizabeth L. Barry,et al.  Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. , 2007, JAMA.

[8]  A. Mazumder,et al.  Quantitative, spatial resolution of the epigenetic field effect in prostate cancer , 2008, The Prostate.

[9]  Vijayalakshmi Ananthanarayanan,et al.  Alpha‐methylacyl‐CoA racemase (AMACR) expression in normal prostatic glands and high‐grade prostatic intraepithelial neoplasia (HGPIN): Association with diagnosis of prostate cancer , 2005, The Prostate.

[10]  J. Tchinda,et al.  Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.

[11]  T. Tammela,et al.  TMPRSS2:ERG Fusion Identifies a Subgroup of Prostate Cancers with a Favorable Prognosis , 2008, Clinical Cancer Research.

[12]  V. Srikantan,et al.  Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome , 2005, Oncogene.

[13]  C C Schulman,et al.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.

[14]  Daniel W Lin,et al.  Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  J. Manivel,et al.  The pattern of CD10 expression in selected pathologic entities of the prostate gland. , 2003, Human pathology.

[16]  M. Toublanc,et al.  Micro-focal prostate cancer: a comparison of biopsy and radical prostatectomy specimen features. , 2005, European urology.

[17]  T. Tolonen,et al.  Bax and Bcl-2 are focally overexpressed in the normal epithelium of cancerous prostates , 2007, Scandinavian journal of urology and nephrology.

[18]  S. Taneja,et al.  Neutral Endopeptidase Protein Expression and Prognosis in Localized Prostate Cancer , 2004, Clinical Cancer Research.

[19]  Gregor Mikuz,et al.  Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma , 1999 .

[20]  Vijayalakshmi Ananthanarayanan,et al.  Evidence for field cancerization of the prostate , 2009, The Prostate.

[21]  D. Bostwick,et al.  High expression of somatostatin receptors and messenger ribonucleic acid for its receptor subtypes in organ-confined and locally advanced human prostate cancers. , 2000, The Journal of clinical endocrinology and metabolism.

[22]  Liang Cheng,et al.  Does pT2b prostate carcinoma exist? Critical appraisal of the 2002 TNM classification of prostate carcinoma , 2004, Cancer.

[23]  J. Moul,et al.  Prostate‐specific antigen‐detected prostate cancer (Stage T1c): An analysis of whole‐mount prostatectomy specimens , 1997, The Prostate.

[24]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[25]  A. Oudes,et al.  HSP27 and HSP70 interact with CD10 in C4‐2 prostate cancer cells , 2007, The Prostate.

[26]  Liang Cheng,et al.  Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens , 2005, Modern Pathology.

[27]  M. Salvatore,et al.  Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. , 1997, The Journal of clinical endocrinology and metabolism.

[28]  S. Taneja,et al.  Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression , 2006, Cancer.

[29]  Rajiv Dhir,et al.  Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors , 2005, BMC Cancer.

[30]  C. R. Leemans,et al.  A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. , 2003, Cancer research.

[31]  S. Srivastava,et al.  Mapping of TMPRSS2–ERG fusions in the context of multi-focal prostate cancer , 2008, Modern Pathology.

[32]  J. Tchinda,et al.  TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.

[33]  W. Catalona,et al.  Serial prostatic biopsies in men with persistently elevated serum prostate specific antigen values. , 1994, The Journal of urology.

[34]  L. True,et al.  Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. , 2004, The American journal of pathology.

[35]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[36]  A. Poustka,et al.  Molecular cancer phenotype in normal prostate tissue. , 2009, European urology.

[37]  S. Horvath,et al.  Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer , 2003, The Prostate.

[38]  Leroy Hood,et al.  A molecular correlate to the Gleason grading system for prostate adenocarcinoma. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[39]  D P Byar,et al.  Carcinoma of the prostate: Prognostic evaluation of certain pathologic features in 208 radical prostatectomies , 1972 .

[40]  C. D. Savci-Heijink,et al.  Identification of Prognostic Biomarkers for Prostate Cancer , 2008, Clinical Cancer Research.

[41]  M. Becich,et al.  Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  J. Gillespie,et al.  Gene promoter methylation in prostate tumor-associated stromal cells. , 2006, Journal of the National Cancer Institute.

[43]  T. Stamey,et al.  Morphologic and clinical significance of multifocal prostate cancers in radical prostatectomy specimens. , 2002, Urology.

[44]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  James R Lambert,et al.  Aberrant HOXC expression accompanies the malignant phenotype in human prostate. , 2003, Cancer research.

[46]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  J. Reubi,et al.  Somatostatin receptors in human prostate and prostate cancer. , 1995, The Journal of clinical endocrinology and metabolism.

[48]  Lawrence D True,et al.  Differential expression of CD10 in prostate cancer and its clinical implication , 2007, BMC urology.

[49]  D. Bostwick,et al.  Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. , 1998, Urology.

[50]  Mustafa Ozen,et al.  Global Gene Expression Analysis of Reactive Stroma in Prostate Cancer , 2009, Clinical Cancer Research.